Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE KIT versus LIDOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE KIT versus LIDOPEN.
BUPIVACAINE HYDROCHLORIDE KIT vs LIDOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine is an amide-type local anesthetic that blocks sodium channels in neuronal cell membranes, inhibiting the propagation of action potentials and thus producing local anesthesia and analgesia.
Lidocaine is a sodium channel blocker, stabilizing neuronal membranes by inhibiting the influx of sodium ions, thereby preventing the propagation of action potentials and producing local anesthesia.
0.25% to 0.5% solution administered via epidural, peripheral nerve block, or local infiltration; maximum single dose 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000); may repeat every 3-6 hours as needed, not to exceed 400 mg in 24 hours.
Lidocaine 2% topical gel: Apply 1-2 grams (approximately 5-10 cm ribbon) to affected area every 4-6 hours as needed, not to exceed 5 grams per day. For infiltration anesthesia: 1% solution, 0.5-5 mL injected locally; maximum 4.5 mg/kg.
None Documented
None Documented
Terminal elimination half-life is 2.7 to 3.5 hours in adults, prolonged in neonates (8-14 hours) and patients with hepatic impairment. Clinically, this supports intermittent dosing or continuous infusion monitoring.
1.5–2 hours (terminal); prolonged in hepatic impairment
Primarily hepatic metabolism (approx. 95%) to metabolites (e.g., pipecoloxylidine, desbutylbupivacaine); less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for a minor fraction. Renal clearance of unchanged drug is about 2-6%.
Renal (10% unchanged; 80% as metabolites), biliary/fecal (10%)
Category C
Category C
Local Anesthetic
Local Anesthetic